|Title:||TRC105 (Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Angiosarcoma|
|Session Title:||Poster Session 2 - Soft Tissue Sarcomas - Poster 110|
|Presenter:||K. Kumar Sankhala, M.D., Sarcoma Oncology Research Center, Santa Monica, CA|
|Location:||Corinthia Hotel Lisbon, Lisbon, Portugal|
|Date/Time:||Friday, November 11, 2016, 10:40 AM - 7:00 PM, Western Europe Time|
About TRACONTRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company's clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. - TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact:Casey LoganChief Business Officer(858) 550-0780 ext. firstname.lastname@example.orgInvestor Contact:Andrew McDonaldLifeSci Advisors LLC646-597-6987Andrew@lifesciadvisors.com